Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Mutations of TET2 , IDH1 , IDH2 and ASXL1 In Chronic Myeloid Leukemia.

Catherine Roche-Lestienne, Marceau Alice, Elise Labis, Olivier Nibourel, Valérie Coiteux, Joelle Guilhot, Laurence Legros, MD, Franck Nicolini, MD, PhD, Philippe Rousselot, MD, PhD, Martine Gardembas, Nathalie Helevaut, Cécile Frimat, Francois Guilhot, Claude Preudhomme

Blood (2010) 116 (21): 3377.

https://doi.org/10.1182/blood.V116.21.3377.3377

Published: 2010

Journal Articles

Allogeneic Stem Cell Transplantation for Blast Crisis (BC) Chronic Myelogenous Leukemia (CML) In the Tyrosine Kinase Inhibitors (TKIs) Era. Analysis of Pre-Transplant Variables on Transplant Outcome. On Behalf of the Societe Française De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML

Blood (2010) 116 (21): 2266.

https://doi.org/10.1182/blood.V116.21.2266.2266

Published: 2010

Journal Articles

Properties of CD34 + CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Xiaoyan Jiang, Donna Forrest, Franck Nicolini, Ali Turhan, Joelle Guilhot, Calvin Yip, Tessa Holyoake, Heather Jorgensen, Karen Lambie, Kyi Min Saw, Emily Pang, Ranko Vukovic, Paeta Lehn, Ashley Ringrose, Miao Yu, Ryan R. Brinkman, Clay Smith, Allen Eaves, Connie Eaves

Blood (2010) 116 (12): 2112–2121.

https://doi.org/10.1182/blood-2009-05-222471

Published: 2010

Includes: Supplemental data

Journal Articles

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Franck Nicolini, MD, PhD, Laurence Legros, MD, PhD, Lydia Roy, MD, PhD, Jean-Claude Chomel, MD, Kaddour Chabane, BSc, Sophie Ducastelle, MD, Selim Corm, MD, Mauricette Michallet, MD, PhD, Francois Guilhot, MD, Ali Turhan, MD, PhD, Sandrine Hayette, PhD

Blood (2008) 112 (11): 1103.

https://doi.org/10.1182/blood.V112.11.1103.1103

Published: 2008

Journal Articles

Intensive Consolidation with Clofarabine and Intermediate-Dose Cytarabine (CLARA) in Patients with High-Risk AML in First CR: The ALFA-0702 Pilot Study.

Xavier Thomas, Ida Lobe, Emmanuel Raffoux, Nicolas Boissel, Quoc-Hung Le, Franck Nicolini, Adrienne de Labarthe, Sandrine Hayette, Jean-Michel Cayuela, Hervé Dombret

Blood (2008) 112 (11): 1934.

https://doi.org/10.1182/blood.V112.11.1934.1934

Published: 2008

Journal Articles

Imatinib Mesylate Dose Escalation Improves Disease Response in Chronic-Phase Chronic Myeloid Leukaemia Patients after Cytogenetic or Molecular Suboptimal Responses to Standard Doses of Imatinib.

Delphine Rea, MDPhD, Gabriel Etienne, MD, Selim Corm, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Francois-Xavier Mahon, MDPhD, Franck Nicolini, MDPhD

Blood (2007) 110 (11): 1052.

https://doi.org/10.1182/blood.V110.11.1052.1052

Published: 2007

Journal Articles

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

Xiaoyan Jiang, MD, PhD, Donna Forrest, MD, Franck Nicolini, MD, PhD, Karen Lambie, Kyi Min Saw, Emily Pang, Ranko Vukovic, Clayton Smith, MD, Allen Eaves, MD, PhD, Connie Eaves, PhD

Blood (2007) 110 (11): 324.

https://doi.org/10.1182/blood.V110.11.324.324

Published: 2007

Journal Articles

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

Nicholas Heaney, Mark Drummond, Jaspal Kaeda, Franck Nicolini, Richard Clark, George Wilson, Pat Shepherd, Jane Tighe, Lorna McLintock, Timothy Hughes, Tessa L. Holyoake

Blood (2007) 110 (11): 1033.

https://doi.org/10.1182/blood.V110.11.1033.1033

Published: 2007

Journal Articles

Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP).

Andreas Hochhaus, Francis J. Giles, Philipp le Coutre, Michele Baccarani, Norbert Gattermann, Kapil N. Bhalla, Giuliana Alimena, Gert Ossenkoppele, Franck Nicolini, Mark R. Litzow, Ravi Bhatia, Francisco Cervantes, Jim Wang, Richard Woodman, Jorge Cortes, Hagop Kantarjian

Blood (2007) 110 (11): 1038.

https://doi.org/10.1182/blood.V110.11.1038.1038

Published: 2007

Journal Articles

High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study.

Philippe Rousselot, Franck Nicolini, François Xavier Mahon, Delphine Réa, Jérome Jaubert, Christian Berthou, Josy Reiffers, Joelle Guilhot, François Guilhot

Blood (2007) 110 (11): 1039.

https://doi.org/10.1182/blood.V110.11.1039.1039

Published: 2007

Journal Articles

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

Franck Nicolini, MD, Giuliana Alimena, MD, Haifa-Kathrin Al-Ali, MD, Andrey Zaritskey, Zhixiang Shen, MD, Saengsuree Jootar, MD, Graeme Smith, MD, Yanzhi Hsu, Maria Luisa Veronese, David A. Rizzieri

Blood (2007) 110 (11): 2960.

https://doi.org/10.1182/blood.V110.11.2960.2960

Published: 2007

Journal Articles

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

Catherine Roche-Lestienne, PhD, Laureline Deluche, MD, Selim Corm, MD, Isabelle Tigaud, MD, Sami Joha, PhD, Nathalie Philippe, PhD, Sandrine Geffroy, PhD, Jean-Luc Lai, PhD, Franck Nicolini, MD, PhD, Claude Preudhomme, MD, PhD

Blood (2007) 110 (11): 2786.

https://doi.org/10.1182/blood.V110.11.2786.2786

Published: 2007

Journal Articles

European Sub-Registry of Chronic Myelogenous Leukemia (CML) Patients (pts) in Failure after Imatinib Therapy (IFP): Rationale, Study Design and Current Enrollment.

Joelle Guilhot, Florence Tartarin, Markus Pfirmann, Arnon Nagler, Franck Nicolini, Philippe Rousselot, Kimmo Porkka, Gert Ossenkoppele, Jesper Stentoft, Francisco Cervantes, Gianantonio Rosti, Josef Thaler, Philipp le Coutre, Joerg Hasford, Rudiger Hehlmann, Francois Guilhot, European LeukemiaNet

Blood (2006) 108 (11): 4764.

https://doi.org/10.1182/blood.V108.11.4764.4764

Published: 2006

Journal Articles

Variant Philadelphia-Positive Chronic Myeloid Leukemia, der(9) Deletions and Response to Imatinib Mesylate: A Retrospective Multicentric Analysis from the French Fi-LMC Group.

S. Corm, MD, Franck Nicolini, S. Richebourg, F. Huguet, D. Rea, I. Tigaud, N. Dastugue, S. Raynaud, L. Legros, J. van den Akker, F.X. Mahon, F. Maloisel, C. Roche-Lestienne, A. Guerci, C. Preudhomme, V. Eclache

Blood (2006) 108 (11): 2113.

https://doi.org/10.1182/blood.V108.11.2113.2113

Published: 2006

Journal Articles

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

Francois-Xavier Mahon, MD, PhD, Stéphane Picard, MD, Karine Titier, MD, Franck Nicolini, MD, PhD, Dominique Ducint, MD, Nicolas Moore, MD, PhD, Gerald Marit, MD, Patrice Berthaud, MD, Mathieu Molimard, MD, PhD

Blood (2005) 106 (11): 1995.

https://doi.org/10.1182/blood.V106.11.1995.1995

Published: 2005

Journal Articles

Gemtuzumab Ozogamicin (Mylotarg ® ) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML).

Xavier Thomas, Quoc-Hung Le, Emmanuelle Tavernier, Samira Mahmoudi, Youcef Chelghoum, Franck Nicolini, Anne Thiebaut, Jacques Troncy, Daniela Revesz, Mohamed Elhamri, Mauricette Michallet

Blood (2005) 106 (11): 4598.

https://doi.org/10.1182/blood.V106.11.4598.4598

Published: 2005

Journal Articles

Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.

Agnès Guerci, MD, Franck Nicolini, MD, Frederic Maloisel, MD, Selim Corm, MD, Laurence Legros, MD, Françoise Rigal-Huguet, MD, Philippe Rousselot, MD, Krimo Bouabdallah, MD, Martine Gardembas, MD, Anne Vekoff, MD, Jean-Jacques Kiladjian, MD, Martine Delain, MD, François-Xavier Mahon, MD, Claude Preudhomme, MD, Joelle Guilhot, BS, François Guilhot, MD

Blood (2005) 106 (11): 168.

https://doi.org/10.1182/blood.V106.11.168.168

Published: 2005

Journal Articles

Identification of a Rare e8a2 BCR-ABL Fusion Gene in Three Novel Chronic Myeloid Leukemia Patients Treated with Imatinib.

Jean-Michel Cayuela, Philippe Rousselot, Franck Nicolini, Daniel Espinouse, Christophe Ollagnier, M.H. Bui-Thi, Kaddour Chabane, E. Raffoux, Isabelle Tigaud, Jean-Pierre Magaud, Sandrine Hayette

Blood (2005) 106 (11): 4830.

https://doi.org/10.1182/blood.V106.11.4830.4830

Published: 2005

Journal Articles

The K247R Substitution in ABL Tyrosine Kinase Domain Is Not a Mutation Leading to Imatinib Resistance but a Polymorphism Rarely Present in CML Patients and in Normal Subjects.

Kaddour Chabane, Franck Nicolini, Jean-Michel Cayuela, Philippe Rousselot, Xavier Thomas, Annick Bertholin, Mauricette Michallet, Jean-Pierre Magaud, Sandrine Hayette

Blood (2005) 106 (11): 4831.

https://doi.org/10.1182/blood.V106.11.4831.4831

Published: 2005

Journal Articles

B-Cell Depletion and Prevention of Hemolysis in Allogeneic Peripheral Blood Stem Cell Transplantation with Minor ABO Incompatibility.

Emmanuelle Tavernier, MD, Anne Thiebaut, MD, Franck Nicolini, MD, PhD, Quoc Hung Le, MD, Xavier Thomas, MD, PhD, Youcef Chelghoum, MD, Daniela Revesz, MD, Olivier Hecquet, MD, PhD, Philippe Dubost, Jean-Paul Bourgeot, Mauricette Michallet, MD, PhD

Blood (2004) 104 (11): 5151.

https://doi.org/10.1182/blood.V104.11.5151.5151

Published: 2004

NARROW

Mutations of TET2 , IDH1 , IDH2 and ASXL1 In Chronic Myeloid Leukemia.

Properties of CD34 + CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Intensive Consolidation with Clofarabine and Intermediate-Dose Cytarabine (CLARA) in Patients with High-Risk AML in First CR: The ALFA-0702 Pilot Study.

Imatinib Mesylate Dose Escalation Improves Disease Response in Chronic-Phase Chronic Myeloid Leukaemia Patients after Cytogenetic or Molecular Suboptimal Responses to Standard Doses of Imatinib.

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP).

High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study.

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

European Sub-Registry of Chronic Myelogenous Leukemia (CML) Patients (pts) in Failure after Imatinib Therapy (IFP): Rationale, Study Design and Current Enrollment.

Variant Philadelphia-Positive Chronic Myeloid Leukemia, der(9) Deletions and Response to Imatinib Mesylate: A Retrospective Multicentric Analysis from the French Fi-LMC Group.

Quantification of Imatinib in Human Plasma by High Performance Liquid Chromatography-Tandem Mass Spectrometry: Applications to Therapeutic Drug Monitoring of Patients with Chronic Myelogenous Leukemia.

Gemtuzumab Ozogamicin (Mylotarg ® ) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML).

Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.

Identification of a Rare e8a2 BCR-ABL Fusion Gene in Three Novel Chronic Myeloid Leukemia Patients Treated with Imatinib.

The K247R Substitution in ABL Tyrosine Kinase Domain Is Not a Mutation Leading to Imatinib Resistance but a Polymorphism Rarely Present in CML Patients and in Normal Subjects.

B-Cell Depletion and Prevention of Hemolysis in Allogeneic Peripheral Blood Stem Cell Transplantation with Minor ABO Incompatibility.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only